Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)

NCT06501196 is registered in ClinicalTrials.gov with BlossomHill Therapeutics as lead sponsor.

NCT NCT06501196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06501196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Lead sponsor
BlossomHill Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
June 19, 2024
Completion date
June 30, 2027
Enrollment
170 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, leukemia, myeloid, leukemia, myeloid, acute, myelodysplastic syndromes, preleukemia, refractory acute myeloid leukemia